{"id":"NCT00150618","sponsor":"Shire","briefTitle":"Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17","officialTitle":"A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of SPD503 in Children and Adolescents Aged 6-17 With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-03-30","primaryCompletion":"2004-10-07","completion":"2004-10-07","firstPosted":"2005-09-08","resultsPosted":"2009-10-15","lastUpdate":"2021-06-10"},"enrollment":324,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Disorder With Hyperactivity"],"interventions":[{"type":"DRUG","name":"SPD503 (1 mg)","otherNames":["Guanfacine hydrochloride"]},{"type":"DRUG","name":"SPD503 (2 mg)","otherNames":[]},{"type":"DRUG","name":"SPD503 (3 mg)","otherNames":[]},{"type":"DRUG","name":"SPD503 (4 mg)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"SPD503 (Guanfacine HCl) (1 mg)","type":"EXPERIMENTAL"},{"label":"SPD503 (2 mg)","type":"EXPERIMENTAL"},{"label":"SPD503 (3 mg)","type":"EXPERIMENTAL"},{"label":"SPD503 (4 mg)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the efficacy of SPD503 compared to placebo in the treatment of children and adolescents aged 6-17 with ADHD.","primaryOutcome":{"measure":"Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Score at 6 Weeks","timeFrame":"Baseline and 6 weeks","effectByArm":[{"arm":"SPD503 (1 mg)","deltaMin":-19.44,"sd":1.69},{"arm":"SPD503 (2 mg)","deltaMin":-18.09,"sd":1.6},{"arm":"SPD503 (3 mg)","deltaMin":-20,"sd":1.64},{"arm":"SPD503 (4 mg)","deltaMin":-20.57,"sd":1.6},{"arm":"Placebo","deltaMin":-12.69,"sd":1.6}],"pValues":[{"comp":"OG000 vs OG004","p":"0.0041"},{"comp":"OG001 vs OG004","p":"0.0176"},{"comp":"OG002 vs OG004","p":"0.0016"},{"comp":"OG003 vs OG004","p":"0.0006"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["19106767"],"seeAlso":["http://www.fda.gov/opacom/7alerts.html","http://www.intuniv.com/documents/INTUNIV_Full_Prescribing_Information.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":61},"commonTop":["Somnolence","Headache","Fatigue","Upper abdominal pain","Dizziness"]}}